Union Securities

UNION therapeutics is a clinical-stage pharmaceutical company based in Denmark, focused on developing novel treatments for inflammatory and infectious diseases. The company's lead candidate, orismilast, is a potent and selective next-generation PDE4 inhibitor currently in Phase 2 development for multiple immunology indications, including atopic dermatitis, psoriasis, and hidradenitis suppurativa. UNION also advances a pipeline of optimized small molecules, such as niclosamide, targeting various infectious diseases and respiratory conditions. By leveraging its expertise in medicinal chemistry and clinical development, the company aims to provide best-in-class oral and topical therapies for patients with significant unmet medical needs. UNION is led by an experienced management team and has established strategic partnerships with organizations like Innovent Biologics and the University of Cambridge.